Potent anti-hepatoma efficacy of HCCS1 via dual tumor-targeting gene-virotherapy strategy

Oncology Reports

Volumn 20, Issue 5, 2008, Pages 1035-1040

  Zhang, Jian ^a,b   Gan, Yu ^a   Gu, Jinfa ^c   Hu, Jingying ^a   Liu, Xinyuan ^c   Zhao, Xintai ^a  

^a SHANGHAI CANCER INSTITUTE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Conditionally replication competent adenovirus; Gene therapy; Hepatocellular carcinoma; Hepatocellular carcinoma suppressor 1; Progression elevated gene 3promoter

Indexed keywords

HEPATOCELLULAR CARCINOMA SUPPRESSOR 1 PROTEIN; ONCOLYTIC ADENOVIRUS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; E1A PROTEIN; HCCS 1 PROTEIN, HUMAN; HCCS-1 PROTEIN, HUMAN; MYD116 PROTEIN, RAT; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VIRAL GENE THERAPY; ADENOVIRUS; ANIMAL; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; METHODOLOGY; MOUSE; NUDE MOUSE; PROMOTER REGION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, DIFFERENTIATION; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149327398     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000106     Document Type: Article

References (21)

1. Zhao XT, Li JJ, He Y, et al: A novel growth suppressor gene on chromosome 17p13.3 with a high frequency of mutation in human hepatocellular carcinoma. Cancer Res 61: 7383-7387, 2001.
2. Zhao XT, He M, Wan DF, et al: The minimum LOH region defined on chromosome 17p13.3 in human hepatocellular carcinoma with gene content analysis. Cancer Lett 190: 221-232, 2003.
3. Bosch FX, Ribes J, Cléries R, et al: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, 2005.
4. Ruiz J, Qian C, Drozdzik M, et al: Gene therapy of viral hepatitis and hepatocellular carcinoma. J Viral Hepat 6: 17-34, 1999.
5. Mitry RR, Mansour MR, Havlik R, et al: Gene therapy for liver tumours. Adv Exp Med Biol 465: 193-205, 2000.
6. Qian C, Drozdzik M, Caselmann WH, et al: The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 32: 344-351, 2000.
7. Roth JA and Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 89: 21-39, 1997.
8. Gomez-Navarro J, Curiel DT and Douglas JT: Gene therapy for cancer. Eur J Cancer 35: 2040-2053, 1999.
9. Vile RG, Russel SJ and Lemoine NR: Cancer gene therapy: hard lessons and new courses. Gene Ther 7: 2-8, 2000.
10. Robbins PD and Ghivizzani SC: Viral vectors for gene therapy. Pharmacol Ther 1: 35-47, 1998.
11. Bauerschmitz GJ, Barker SD and Hemminki A: Adenoviral gene therapy for cancer: From vectors to targeted and replication-competent agents. Int J Oncol 6: 1161-1174, 2002.
12. Zhang ZL, Zou WG, Luo CX, et al: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13: 481-489, 2003.
13. Zhao LL, Gu JF, Dong AW, et al: Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 16: 845-858, 2005.
14. Zhang YH, Gu JF, Zhao LL, et al: Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res 66: 4291-4298, 2006.
15. Rothmann T, Hengstermann A, Whitaker NJ, et al: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72: 9470-9478, 1998.
16. Ohashi M, Kanai F, Tateishi K, et al: Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem Biophys Res Commun 282: 529-535, 2001.
17. Takahashi M, Sato T, Sagawa T, et al: E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 5: 627-634, 2002.
18. Su ZZ, Sarkar D, Emdad L, et al: Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci USA 102: 1059-1064, 2005.
19. Su ZZ, Shi Y and Fisher PB: Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene 19: 3411-3421, 2000.
20. Liu P, Kimmoun E, Legrand A, et al: Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 37: 63-71, 2002.
21. Abou EI, Hassan MA, Meulen-Muileman van der I, et al: Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol 78: 12243-12251, 2004.